4-(3-(4-hydroxyphenyl)-1H-pyrazolo[3,4-b]pyridin-5-yl)benzene-1,2-diol

ID: ALA4873449

Chembl Id: CHEMBL4873449

PubChem CID: 164625371

Max Phase: Preclinical

Molecular Formula: C18H13N3O3

Molecular Weight: 319.32

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  Oc1ccc(-c2n[nH]c3ncc(-c4ccc(O)c(O)c4)cc23)cc1

Standard InChI:  InChI=1S/C18H13N3O3/c22-13-4-1-10(2-5-13)17-14-7-12(9-19-18(14)21-20-17)11-3-6-15(23)16(24)8-11/h1-9,22-24H,(H,19,20,21)

Standard InChI Key:  QSRKFVZHMMKLIL-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA4873449

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 319.32

Molecular Weight (Monoisotopic): 319.0957

AlogP: 3.41

#Rotatable Bonds: 2

Polar Surface Area: 102.26

Molecular Species: NEUTRAL

HBA: 5

HBD: 4

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 4

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 8.90

CX Basic pKa: 1.91

CX LogP: 3.22

CX LogD: 3.20

Aromatic Rings: 4

Heavy Atoms: 24

QED Weighted: 0.42

Np Likeness Score: -0.23

References

1. Park A, Hwang J, Lee JY, Heo EJ, Na YJ, Kang S, Jeong KS, Kim KY, Shin SJ, Lee H..  (2021)  Synthesis of novel 1H-Pyrazolo[3,4-b]pyridine derivatives as DYRK 1A/1B inhibitors.,  47  [PMID:34182093] [10.1016/j.bmcl.2021.128226]

2. Lindberg MF, Deau E, Arfwedson J, George N, George P, Alfonso P, Corrionero A, Meijer L..  (2023)  Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases.,  66  (6): [PMID:36876904] [10.1021/acs.jmedchem.2c02068]

Source

Source(1):

• Scientific Literature